ABBV

AbbVie Inc.

Quarterly revenue, EPS, free cash flow, valuation, and Rule of 40 scores for AbbVie Inc..

R40: 51$370.06B
$208.84-8.65 (-3.98%)● Live
Current Narrative

AbbVie is seen as pivoting successfully post-Humira cliff, with strong Q4 beats, robust FY26 guidance, and aggressive obesity focus driving optimism. Sentiment is positive on growth from immunology/neuroscience and M&A potential, but cautious on busted deals and competition in obesity—market views it as undervalued for recovery.

News

Latest Coverage

NewsFeb 4

AbbVie Posts Double Beat for Q4

Q4 EPS $2.71 vs $2.65 est, revenue $16.62B vs $16.42B est; FY26 EPS guidance $14.37-$14.57 vs $14.24 est, signaling robust earnings growth.

Investing.com
NewsFeb 2

AbbVie All In on Obesity

AbbVie signals heavy obesity focus without explicit statement; expected to compete with Novo Nordisk, Merck, Bristol-Myers Squibb, emphasizing efficacy over oral vs. subcutaneous.

Fierce Pharma
NewsJan 29

AbbVie at JPM is All In on Obesity

AbbVie expresses enthusiasm for phase 1-2 obesity assets; anticipates big showdown with competitors like Novo Nordisk, Merck, and Lilly in weeks, not months.

BioSpace
NewsJan 28

Biopharma Sentiment Just Snapped Higher

Biopharma sentiment surged with BPSI index jumping 78 to 90; aligns with public market price action and deal flow, expecting continued M&A and IPO activity into summer.

@BowTiedBiotech on X
See all news →
Rule of 402025 Q3
51.2
✓ Passing
Revenue Growth YoY+9.1%
+
FCF Margin+42.1%
History
26
Q4
2023 R40 +34
32
Q1
18
Q2
40
Q3
50
Q4
2024 R40 +35
19
Q1
38
Q2
51
Q3
ANALYST RATINGS
Buy$239
ABBV
Neutral$240
Resumed
2026-01-07
Buy$265
Upgrade
2025-12-10
Sector Outperform$280
Initiated
2025-11-13
Hold$237
Downgrade
2025-11-04
Buy$270
Upgrade
2025-09-17
See all 16 ratings →
Revenue
2025Q3$15.8B
*Qtr, USD
EPS
0
2025Q3$0.10
*Qtr, USD per share
P/E Ratio
2025Q3172.76
*Qtr, x
Free cash flow
0
2025Q3$6.6B
*Qtr, USD
Shares
Loading...
Cumulative FCF
2025Q3$173.1B
*Running total, USD
Company timeline

Earnings release dates

QuarterEnd datePublication dateSource
2025 Q42025-12-312026-02-04Link
2025 Q32025-09-302025-10-31Link
2025 Q22025-06-302025-07-31Link
2025 Q12025-03-312025-04-25Link
2024 Q42024-12-312025-01-31Link
2024 Q32024-09-302024-10-30Link
2024 Q22024-06-302024-07-25Link
2024 Q12024-03-312024-04-26Link
2023 Q42023-12-312024-02-02Link
2023 Q32023-09-302023-10-27Link
2023 Q22023-06-302023-07-27Link
2023 Q12023-03-312023-04-27Link
2022 Q42022-12-312023-02-09Link
2022 Q32022-09-302022-10-28Link
2022 Q22022-06-302022-07-29Link
2022 Q12022-03-312022-04-29Link
2021 Q42021-12-312022-02-02Link
2021 Q32021-09-302021-10-29Link
2021 Q22021-06-302021-07-30Link
2021 Q12021-03-312021-04-30Link
2020 Q42020-12-312021-02-03Link
2020 Q32020-09-302020-10-30Link
2020 Q22020-06-302020-07-31Link
2020 Q12020-03-312020-05-01Link
Background

Company History

ExchangeNYSE
IPO DateJan 2, 2013
IPO Price$35.29
Shares Outstanding1.77Bi
2012
Spin-Off from Abbott Laboratories
AbbVie was formed as a spin-off from Abbott Laboratories, focusing on research-based pharmaceuticals; became independent on January 1, 2013.
2014
Acquisition of ImmuVen
Acquired ImmuVen, a startup focused on biotherapeutics for cancer, infectious diseases, and autoimmune disorders.
2015
Pharmacyclics Acquisition
Acquired oncology firm Pharmacyclics and its blood cancer treatment ibrutinib for $21 billion.
2019
$63B Allergan Acquisition
Acquired Allergan for $63 billion, with divestitures to gain regulatory approval, including brazikumab to AstraZeneca and Zenpep/Viokace to Nestlé.
2020
COVID-19 Treatment Evaluation
Evaluated Kaletra (lopinavir/ritonavir) as a potential COVID-19 treatment, later found ineffective, and ceased patent enforcement in response to government pressure.
2024
$10.1B ImmunoGen Acquisition
Acquired ImmunoGen for $10.1 billion to enter the ovarian cancer market with the drug Elahere.
2024
CEO Change
Robert Michael replaced Richard Gonzalez as CEO, with Gonzalez becoming executive chairman.
Leadership

Key Players

Robert A. Michael
Chairman of the Board & CEO
Became CEO in 2024, added Chairman role effective July 2025; previously President & COO, CFO; 30+ years at Abbott/AbbVie.
Scott T. Reents
EVP, Chief Financial Officer
Named CFO in June 2022; previously VP of Tax and Treasury; joined the company in 2013.
Jeffrey Stewart
EVP, Chief Commercial Officer
Leads global commercial operations across all therapeutic areas and the Allergan Aesthetics portfolio.
Roopal Thakkar, M.D.
EVP, R&D & Chief Scientific Officer
Appointed July 2024; leads 14,000+ R&D team members; drives pipeline across immunology, oncology, neuroscience, and eye care.
Azita Saleki-Gerhardt, Ph.D.
EVP, Chief Operations Officer
Oversees global manufacturing, supply chain, quality, and enterprise services for all AbbVie products.
Perry Siatis
EVP, General Counsel & Secretary
Promoted to General Counsel in late 2022; succeeded Laura Schumacher; previously SVP and Deputy General Counsel.
Short Interest

Short interest data unavailable for ABBV.

Related

Similar stocks in Healthcare

Johnson & JohnsonJNJJohnson & JohnsonEli Lilly and CompanyLLYEli Lilly and CompanyUnitedHealth Group IncorporatedUNHUnitedHealth Group IncorporatedHims & Hers Health, Inc.HIMSHims & Hers Health, Inc.